

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances:

Lyophilisate (live attenuated):

Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15

Minimum

$10^{3.1}$ TCID₅₀*

Maximum

$10^{5.1}$ TCID₅₀*

Suspension (inactivated):

Leptospira interrogans serogroup Icterohaemorrhagiae

serovar Icterohaemorrhagiae strain MSLB 1089

ALR** titre \geq 1:51

Leptospira interrogans serogroup Canicola

serovar Canicola, strain MSLB 1090

ALR** titre \geq 1:51

Leptospira kirschneri serogroup Grippotyphosa

serovar Grippotyphosa, strain MSLB 1091

ALR** titre \geq 1:40

Leptospira interrogans serogroup Australis

serovar Bratislava, strain MSLB 1088

ALR** titre \geq 1:51

Rabies virus, strain SAD Vnukovo-32

\geq 5 IU***

* Tissue culture infectious dose 50%.

** Antibody micro agglutination-lytic reaction.

*** International units.

Adjuvant:

Aluminium hydroxide

1.8 - 2.2 mg.

Excipients:

Qualitative composition of excipients and other constituents
Lyophilisate:
Trometamol
Edetic Acid
Sucrose
Dextran 70
Suspension:
Sodium chloride
Potassium chloride
Potassium dihydrogen phosphate
Disodium phosphate dodecahydrate
Water for injections

The visual appearance is as follows:

Lyophilisate: spongy matter of white colour.

Suspension: pink colour with fine sediment.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

Active immunisation of dogs from 8-9 weeks of age:

- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
- to prevent clinical signs, infection and urinary excretion caused by *L. interrogans* serogroup Australis serovar Bratislava,
- to prevent clinical signs and urinary excretion and reduce infection caused by *L. interrogans* serogroup Canicola serovar Canicola and *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae,
- to prevent clinical signs and reduce infection and urinary excretion caused by *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa and
- to prevent mortality, clinical signs and infection caused by rabies virus.

Onset of immunity:

- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for *Leptospira* components.

Duration of immunity:

At least three years following the primary vaccination course for rabies. At least one year following the primary vaccination course for canine parainfluenza virus and *Leptospira* components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.

3.3 Contraindications

None.

3.4 Special warnings

A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

The live attenuated virus vaccine strain CPiV may be shed by vaccinated dogs following vaccination. However, due to the low pathogenicity of the strain, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Common (1 to 10 animals / 100 animals treated):	injection site swelling ¹
Rare (1 to 10 animals / 10,000 animals treated):	hypersensitivity reaction ² (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis

¹A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

²If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Subcutaneous use.

Dose and route of administration:

Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Appearance of the reconstituted vaccine: pink/red, or yellowish colour with light opalescence.

Primary vaccination scheme:

Two doses of Versican Plus Pi/L4R 3-4 weeks apart from 8-9 weeks of age. The second dose should not be given before 12 weeks of age.

Rabies:

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. Therefore, the first dose may be given using Versican Plus Pi/L4. In this case the second vaccination with Versican Plus Pi/L4R should not be given before 12 weeks.

However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).

In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6-week old dogs.

Re-vaccination scheme:

A single dose of Versican Plus Pi/L4R should be given every 3 years. Annual re-vaccination is required for canine parainfluenza virus and *Leptospira* components. Therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse events other than those mentioned in section 3.6 were observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Official control authority batch release is required for this product.

3.12 Withdrawal periods

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI07AJ.

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parainfluenza virus, *Leptospira interrogans* serogroup Australis serovar Bratislava, *Leptospira interrogans* serogroup Canicola serovar Canicola, *Leptospira kirschneri* serogroup Grippotyphosa serovar Grippotyphosa, *Leptospira interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after reconstitution according to directions: use immediately.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

5.4 Nature and composition of immediate packaging

Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.

Type 1 glass vial containing 1 ml of suspension closed with a chlorobutyl rubber stopper and aluminium cap.

Pack sizes:

Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of suspension.

Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of suspension.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

7. MARKETING AUTHORISATION NUMBERS

EU/2/14/173/001

EU/2/14/173/002

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 31/07/2014.

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database.

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**BOX****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection.

2. STATEMENT OF ACTIVE SUBSTANCES

Each dose of 1 ml contains:

Active substances:**Lyophilisate (live attenuated):**

Canine parainfluenza virus Type 2

Minimum

$10^{3.1}$ TCID₅₀

Maximum

$10^{5.1}$ TCID₅₀

Suspension (inactivated):

L. interrogans serovar Icterohaemorrhagiae

ALR titre \geq 1:51

L. interrogans serovar Canicola

ALR titre \geq 1:51

L. kirschneri serovar Grippotyphosa

ALR titre \geq 1:40

L. interrogans serovar Bratislava

ALR titre \geq 1:51

Rabies virus

\geq 5 IU

3. PACKAGE SIZE

25 x 1 dose

50 x 1 dose

4. TARGET SPECIES

Dogs.

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

14. MARKETING AUTHORISATION NUMBERS

EU/2/14/173/001
EU/2/14/173/002

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
VIAL (1 DOSE LYOPHILISATE)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus Pi/L4R



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Pi
1 dose

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}
Once reconstituted use immediately.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
VIAL (1 ML SUSPENSION)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus Pi/L4R



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

L4R
1 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection for dogs

2. Composition

Each dose of 1 ml contains:

Active substances:

Lyophilisate (live attenuated):

Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15

Minimum

$10^{3.1}$ TCID₅₀*

Maximum

$10^{5.1}$ TCID₅₀*

Suspension (inactivated):

Leptospira interrogans serogroup Icterohaemorrhagiae

serovar Icterohaemorrhagiae strain MSLB 1089

ALR** titre \geq 1:51

Leptospira interrogans serogroup Canicola

serovar Canicola, strain MSLB 1090

ALR** titre \geq 1:51

Leptospira kirschneri serogroup Grippotyphosa

serovar Grippotyphosa, strain MSLB 1091

ALR** titre \geq 1:40

Leptospira interrogans serogroup Australis

serovar Bratislava, strain MSLB 1088

ALR** titre \geq 1:51

Rabies virus, strain SAD Vnukovo-32

\geq 5 IU***

* Tissue culture infectious dose 50%.

** Antibody micro agglutination-lytic reaction.

*** International units.

Adjuvant:

Aluminium hydroxide

1.8 - 2.2 mg.

The visual appearance is as follows:

Lyophilisate: spongy matter of white colour.

Suspension: pink colour with fine sediment.

3. Target species

Dogs.

4. Indications for use

Active immunisation of dogs from 8-9 weeks of age:

- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
- to prevent clinical signs, infection and urinary excretion caused by *L. interrogans* serogroup Australis serovar Bratislava,
- to prevent clinical signs and urinary excretion and reduce infection caused by *L. interrogans* serogroup Canicola serovar Canicola and *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae,
- to prevent clinical signs and reduce infection and urinary excretion caused by *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa and

- to prevent mortality, clinical signs and infection caused by rabies virus.

Onset of immunity:

- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after the completion of primary course for *Leptospira* components.

Duration of immunity:

At least three years following the primary vaccination course for rabies. At least one year following the primary vaccination course for canine parainfluenza virus and *Leptospira* components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.

5. Contraindications

None.

6. Special warnings

Special warnings:

A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

The live attenuated virus vaccine strain CPiV may be shed by vaccinated dogs following vaccination. However, due to the low pathogenicity of the strain, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse events other than those mentioned in section 7 (Adverse events) were observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.

Special restrictions for use and special conditions for use:

Official control authority batch release is required for this product.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Dogs:

Common (1 to 10 animals / 100 animals treated):
injection site swelling ¹
Rare (1 to 10 animals / 10,000 animals treated):
hypersensitivity reaction ² (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis

¹A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

²If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Subcutaneous use.

Primary vaccination scheme:

Two doses of Versican Plus Pi/L4R 3-4 weeks apart from 8-9 weeks of age. The second dose should not be given before 12 weeks of age.

Rabies:

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. Therefore, the first dose may be given using Versican Plus Pi/L4. In this case the second vaccination with Versican Plus Pi/L4R should not be given before 12 weeks.

However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).

In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6-week old dogs.

Re-vaccination scheme:

A single dose of Versican Plus Pi/L4R should be given every 3 years. Annual re-vaccination is required for canine parainfluenza and *Leptospira* components. Therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

9. Advice on correct administration

Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Appearance of the reconstituted vaccine: pink/red, or yellowish colour with light opalescence.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/14/173/001-002

Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of suspension.

Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of suspension.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the Union Product Database.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis Belgium
Rue Laid Burniat 1
1348 Louvain-La-Neuve
Belgium

België/Belgique/Belgien
Tél/Tel: +32 (0) 800 99 189
pharmvig-belux@zoetis.com

Република България
Тел: +359 888 51 30 30
zoetisromania@zoetis.com

Česká republika
Tel: +420 257 101 111
infovet.cz@zoetis.com

Danmark
Tlf: +45 70 20 73 05
adr.scandinavia@zoetis.com

Deutschland
Tel: +49 30 2020 0049
tierarzneimittelsicherheit@zoetis.com

Eesti
Tel: +370 610 05088
zoetis.estonia@zoetis.com

Ελλάδα
Τηλ: +30 210 6791900
infoqr@zoetis.com

España
Tel: +34 91 4191900
regulatory.spain@zoetis.com

France
Tél: +33 (0)800 73 00 65
contacteznous@zoetis.com

Hrvatska
Tel: +385 1 6441 462
pv.westernbalkans@zoetis.com

Lietuva
Tel: +370 610 05088
zoetis.lithuania@zoetis.com

Luxembourg/Luxemburg
Tél/Tel: +32 (2) 746 80 11
pharmvig-belux@zoetis.com

Magyarország
Tel.: +36 1 224 5200
hungary.info@zoetis.com

Malta
Tel: +356 21 465 797
info@agrimedltd.com

Nederland
Tel: +31 (0)10 714 0900
pharmvig-nl@zoetis.com

Norge
Tlf: +47 23 29 86 80
adr.scandinavia@zoetis.com

Österreich
Tel: +43 (0)1 2701100 100
tierarzneimittelsicherheit@zoetis.com

Polska
Tel.: +48 22 2234800
pv.poland@zoetis.com

Portugal
Tel: +351 21 042 72 00
zoetis.portugal@zoetis.com

România
Tel: +40785019479
zoetisromania@zoetis.com

Ireland

Tel: +353 (0) 1 256 9800
pvsupportireland@zoetis.com

Ísland

Sími: +354 540 8000
icepharma@icepharma.is

Italia

Tel: +39 06 3366 8111
farmacovigilanza.italia@zoetis.com

Κύπρος

Τηλ: +30 210 6791900
infoqr@zoetis.com

Latvija

Tel: +370 610 05088
zoetis.latvia@zoetis.com

Slovenija

Tel: +385 1 6441 462
pv.westernbalkans@zoetis.com

Slovenská republika

Tel: +420 257 101 111
infovet.cz@zoetis.com

Suomi/Finland

Puh/Tel: +358 10 336 7000
laaketurva@zoetis.com

Sverige

Tel: +46 (0) 76 760 0677
adr.scandinavia@zoetis.com

United Kingdom (Northern Ireland)

Tel: +353 (0) 1 256 9800
pvsupportireland@zoetis.com

Manufacturer responsible for batch release:

Bioveta a.s.
Komenskeho 212/12
683 23 Ivanovice Na Hane
Czechia

17. Other information

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parainfluenza virus, *Leptospira interrogans* serogroup Australis serovar Bratislava, *Leptospira interrogans* serogroup Canicola serovar Canicola, *Leptospira kirschneri* serogroup Grippotyphosa serovar Grippotyphosa, *Leptospira interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and rabies virus.